期刊文献+

人非小细胞肺癌与外周血淋巴细胞表达LRP的相关性研究 被引量:1

Correlation between expression of lung resistance-related protein in non-small cell lung cancer and that in peripheral blood lymphocytes
下载PDF
导出
摘要 目的探讨肺耐药相关蛋白(lung resistance-related protein,LRP)在人非小细胞肺癌(non-small cell lung cancer,NSCLC)癌组织、癌旁组织和外周血淋巴细胞(peripheral blood lymphocytes,PBL)中的表达及其相关性。方法采用S-P免疫组织化学方法检测49例人NSCLC癌组织、癌旁组织和PBL中LRP的表达及10例正常人PBL中LRP的表达。结果NSCLC癌组织、癌旁组织和PBL的LRP表达阳性率分别为78.2%、46.4%和66.8%,其中癌组织的LRP表达阳性率明显高于癌旁组织(P<0.05),且与PBL的LRP表达呈正相关。在各病理类型的NSCLC中,腺癌表达阳性率最高(90.9%),鳞癌次之(55.6%),差异显著(P<0.01)。10例正常人PBL的LRP表达阳性率(20%)显著低于NSCLC患者(P<0.05)。结论检测NSCLC患者PBL的LRP表达可间接反映癌组织的LRP表达状况。 Objective To explore the correlation between the expression of lung resistance-related protein (LRP) in non-small cell lung cancer (NSCLC) and that in peripheral blood lymphocytes (PBL). Methods The S-P immunohistochemistry was used to detect the expression of LRP in specimens and PBL of 49 patients with NSCLC. Para-carcinoma tissues and PBL of 10 normal people were used as controls. Results The positive expression rate of LRP was 78.2% , 46.4% and 66.8% in carcinoma tissues, para-carcinoma tissues and PBL, respectively. The expression rate of LRP in carcinoma tissues was higher than that in para-carcinoma tissues ( P 〈 0.05 ) , and positively correlated with that in PBL of the patients. The expression rate of LRP in adenocarcinomas was higher than that in squamous cell carcinomas ( P 〈 0.01 ). The expression rate of LRP in the normal people was lower than in NSCLC patients(P 〈 0.05 ). Conclusion The expression of LRP in PBL of NSCLC patients may indirectly represent the expression of LRP in carcinoma tissues.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2007年第17期1699-1701,共3页 Journal of Third Military Medical University
关键词 肺耐药相关蛋白 非小细胞肺癌 外周血淋巴细胞 lung resistance-related protein non-small cell lung cancer peripheral blood lymphocytes
  • 相关文献

参考文献13

  • 1姬明丽,宋晓荣,千智斌,李光华.非小细胞肺癌组织Bcl-2蛋白的表达和多药耐药检测[J].郑州大学学报(医学版),2006,41(5):919-921. 被引量:2
  • 2Meschini S,Marra M,Calcabrini A,et al.Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells[J].Toxicol In Vitro,2002,16(4):389-398.
  • 3Rybarova S,Hodorova I,Hajdukova M,et al.Expression of MDR proteins in breast cancer and its correlation with some clinical and pathological parameters[J].Neoplasma,2006,53(2):128-135.
  • 4Sunnaram B L,Gandemer V,Sebillot M,et al.LRP overexpression in monocytic lineage[J].Leuk Res,2003,27(8):755-759.
  • 5Harada T,Ogura S,Yamazaki K,et al.Predictive value of expression of P53,Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers[J].Cancer Sci,2003,94(4):394-399.
  • 6Volm M,Koomagi R,Mattern J,et al.Protein expression profiles indicative for drug resistance of non-small cell lung cancer[J].Br J Cancer,2002,87(3):251-257.
  • 7Rudas M,Filipits M,Taucher S,et al.Expression of MRP1,LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy[J].Breast Cancer Res Treat,2003,81(2):149-157.
  • 8Horvath V,Blanarova O,Svihalkova-Sindlerova L,et al.Platinum(Ⅳ) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells[J].Gynecol Oncol,2006,102(1):32-40.
  • 9Wang W,Ke S,Chen G,et al.Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines[J].Oncol Rep,2004,12(6):1365-1370.
  • 10Rybarova S,Hajdukova M,Hodorova I,et al.Expression of the multidrug resistance-associated protein 1 (MRP1) and the lung resistance-related protein (LRP) in human lung cancer[J].Neoplasma,2004,51(3):169-174.

二级参考文献20

共引文献19

同被引文献8

  • 1耿志坚,陈晓峰,乔庆,童淑兰,方立德,徐亮,李强,陈维香,丁珺.肺癌中p53及nm23与多药耐药基因表达的相关分析及预后意义[J].中国肿瘤临床与康复,2005,12(1):10-12. 被引量:5
  • 2Miyatake K, Gemba K, Ueoka H, et al. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable nonsmall cell lung cancer[J]. Anticancer Res, 2003,23 (3): 2829.
  • 3Wachters FM, Wong LS, TimensW, et al. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage Ⅲ/Ⅳ NSCLC patients treated with chemotherapy [J]. Lung Cancer, 2005,50(2) : 211.
  • 4Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells[J]. Cell, 1979,17(1) :43.
  • 5Morgunkova AA, Almazov VP, Strunina SM, et al. Dominant-negative inactivation of p53:the effect of the proportion between trans dominant inhibitor and its target[J]. Mol Biol (Mosk), 2003,37(1) :112.
  • 6Kawasaki M,Nakanishi Y,Kuwano K,et al. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis ant] chemoresistance in advanced non-small cell lung cancer[J]. Clin Cancer Res,1997,3(7) :1195.
  • 7Rosell R, Gonzalez JL, Alberola V, et al. Single-agent paclitaxel by 3 hour infusion in the treatment of non-small cell lung cancer:links between p53 and K-ras gene status and chemosensitivity[J]. Semin Oncol, 1995,22(6) :12.
  • 8沈宗丽,周振英,朱月清,吴晓柳.肿瘤患者外周血淋巴细胞p53高表达的临床意义[J].肿瘤学杂志,2002,8(2):92-93. 被引量:6

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部